Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$7.9M
Filings
36
Firms Hired
1
Active Period
2001–2012
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Clean Environment and Stable Energy Market Act of 2009
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, icluding: S. 868 and H.R. 1683, the State Flexibility Act ( MOE). Issues realting to inclusion of palliative care as a bundled service within CMS "value-based purcahsing".
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 1683
Quality Cancer Care for Life Act of 2010
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 5560
To repeal mandatory funding provided to States in the Patient Protection and Affordable Care Act to establish American Health Benefit Exchanges.
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 1213
To repeal the Prevention and Public Health Fund.
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 1217
MLR Repeal Act of 2011
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 2077
Preserving Access to Life-Saving Medications Act of 2011
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 2245
Startup Expansion and Investment Act
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 2941
Health Equity and Accountability Act of 2011
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 2954
BPCA and PREA Reauthorization Act of 2012
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 4274
Colorectal Cancer Prevention, Early Detection, and Treatment Act
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 912
Fee Repeal and Expanded Access Act of 2009
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, icluding: S. 868 and H.R. 1683, the State Flexibility Act ( MOE). Issues realting to inclusion of palliative care as a bundled service within CMS "value-based purcahsing".
Client expense: $20,000 · Firm income: —
Matched citations: S. 868
SUN Act
2012 · third_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Client expense: $20,000 · Firm income: —
Matched citations: S. 1064
Clean Environment and Stable Energy Market Act of 2009
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including: S. 868 and H.R. 1683, the State Flexibility Act (MOE). Issues relating to inclusion of palliative care as a bundled service with CMS "value-based purchasing".
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 1683
Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 3974
Lymphedema Diagnosis and Treatment Cost Saving Act of 2010
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 4662
Quality Cancer Care for Life Act of 2010
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 5560
To repeal mandatory funding provided to States in the Patient Protection and Affordable Care Act to establish American Health Benefit Exchanges.
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 1213
To repeal the Prevention and Public Health Fund.
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 1217
MLR Repeal Act of 2011
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 2077
Startup Expansion and Investment Act
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 2941
Health Equity and Accountability Act of 2011
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 2954
STOP Act
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environmernts including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations form the Executive in Need of Scrutiny Act of 2011; (4) Framework Convention on Tobacco Control (FCTC): and (5) issues relating to NIH reorganization. Legislation includes H.R. 3186 and S. 1706, Smuggled Tobacco Prevention Act; H.R. 3382, Smoke-Free Federal Building Act; S. 1403, IDEA Full Funding Act; and H.R. 65: Candy Tobacco Tax Parity Act of 2011. Issues related to cigar regulation on H.R. 5973.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 3186
Smoke-Free Federal Buildings Act
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environmernts including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations form the Executive in Need of Scrutiny Act of 2011; (4) Framework Convention on Tobacco Control (FCTC): and (5) issues relating to NIH reorganization. Legislation includes H.R. 3186 and S. 1706, Smuggled Tobacco Prevention Act; H.R. 3382, Smoke-Free Federal Building Act; S. 1403, IDEA Full Funding Act; and H.R. 65: Candy Tobacco Tax Parity Act of 2011. Issues related to cigar regulation on H.R. 5973.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 3382
BPCA and PREA Reauthorization Act of 2012
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 4274
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
2012 · second_quarter · Firm: AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environmernts including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations form the Executive in Need of Scrutiny Act of 2011; (4) Framework Convention on Tobacco Control (FCTC): and (5) issues relating to NIH reorganization. Legislation includes H.R. 3186 and S. 1706, Smuggled Tobacco Prevention Act; H.R. 3382, Smoke-Free Federal Building Act; S. 1403, IDEA Full Funding Act; and H.R. 65: Candy Tobacco Tax Parity Act of 2011. Issues related to cigar regulation on H.R. 5973.
Client expense: $420,000 · Firm income: —
Matched citations: H.R. 5973
Source: Senate LDA